Avenue Therapeutics Inc
avenuetx.comWhat Do They Do?
Develops drug candidates for neurologic diseases, including Pompe disease and postoperative acute pain.
10-K for FY2025, filed Mar 30, 2026Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and…View ↗
ATX-04 is an investigational, orally administered, small molecule therapy that we are developing for the treatment of Pompe disease, as an…View ↗
Under the terms of certain agreements described herein, we have an exclusive license with Revogenex to develop and commercialize IV…View ↗
How Do They Make Money?
Avenue has received payment for transferring drug rights, with payment tied to the transfer; agreements also provide for later development and regulatory milestone payments and royalties tied to sales.
10-K for FY2025, filed Mar 30, 2026Also under the Termination and Transfer Agreement, AnnJi agreed to make payments to us of $1.6 million net of 20% tax withholding, with…View ↗
In November 2025, we sold Baergic to Axsome pursuant to a stock purchase agreement (the “Baergic Agreement”), pursuant to which Axsome: (i)…View ↗
Avenue and the other former stockholders of Baergic will be eligible to receive from Axsome:View ↗
Avenue is eligible to receive approximately 74% of all future payments and royalties payable under the Baergic Agreement.View ↗
$1.4M
-
10-K for FY2025, filed Mar 30, 2026
$1.4M ↗
Do Revenues Turn Into Profits?
No. It lost $2.9M in FY2025.
10-K for FY2025, filed Mar 30, 2026
How Are They Changing?
Portfolio focus
The older report listed candidates for spinal and bulbar muscular atrophy, postoperative pain, epilepsy and panic disorders; the latest centers on Pompe disease and postoperative pain, after rights to former candidates were transferred or sold.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and…View ↗
Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and…View ↗
On April 24, 2025 (the “Termination Effective Date”), Avenue and AnnJi entered into a License Termination and Program Transfer Agreement…View ↗
In November 2025, we sold Baergic to Axsome pursuant to a stock purchase agreement (the “Baergic Agreement”), pursuant to which Axsome: (i)…View ↗
Contingent income
Potential income from former programs now depends on milestone payments and royalties from AnnJi and Axsome, rather than Avenue developing those rights itself.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026On April 24, 2025 (the “Termination Effective Date”), Avenue and AnnJi entered into a License Termination and Program Transfer Agreement…View ↗
In November 2025, we sold Baergic to Axsome pursuant to a stock purchase agreement (the “Baergic Agreement”), pursuant to which Axsome: (i)…View ↗
Avenue and the other former stockholders of Baergic will be eligible to receive from Axsome:View ↗
Avenue is eligible to receive approximately 74% of all future payments and royalties payable under the Baergic Agreement.View ↗
Who Do They Compete With?
Competes with Sanofi, Amicus, Latigo Biotherapeutics, Eli Lilly, Dogwood Therapeutics, and Concentric Analgesics
10-K for FY2025, filed Mar 30, 2026We believe that ATX-04, if approved, will be used in combination with existing approved ERTs including Myozyme/Lumizyme (Sanofi) and…View ↗
Loading...
